According to Future Market Insights, the DNA Methylation Market is expected to grow at a 15% CAGR between 2023 and 2033. The global market for DNA methylation is expected to reach US$ 5815.49 million by 2033. In addition, the rising prevalence of esophageal adenocarcinoma has contributed to the overall increase. According to the American Cancer Society (ACS), an estimated 20,640 esophageal cancer cases will go undiagnosed in the United States in 2022. The chronic disease claimed the lives of 16,410 people.
Get a Sample PDF of the Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15893
Growing esophageal cancer cases in the United States highlight the critical need for early intervention measures that can help improve patients’ low survival rates. A study published in October 2022 by Fred Hutchinson Cancer Research Center stated that methylated DNA biomarkers could be used to detect esophageal adenocarcinoma and high-grade dysplasia.
The significant increase in the adoption of epigenetics-based treatment strategies, combined with the widespread commercialization of nucleic acid-based diagnostic tests and kits, is expected to drive market growth. An article published in PubMed in May 2022 stated that epigenetics-based treatment strategies will be used to study Alzheimer’s disease.
Furthermore, key market players are undertaking a variety of initiatives such as new product development, strategic alliance formation, and regional expansion, among others. All of these factors are positively influencing the DNA methylation market demand.
Key Takeaways from the Market Study
- In terms of technology, sequencing is expected to account for 35% of the DNA methylation market in 2023.
- Consumables are expected to account for 35% of the DNA methylation market in 2023.
- Clinical research is expected to have a 40% market share of the DNA methylation market in 2023.
- The diagnostic segment is expected to grow at the fastest rate in the coming years, with a CAGR of 16%.
- The pharmaceutical and biotechnology end-use segments are expected to account for 42% of the DNA methylation market in 2023.
- North America is expected to hold 40% of the DNA methylation market in 2023.
- By 2023, Asia Pacific is expected to hold 38% of the DNA methylation market.
“Government funding and R&D expenditure are expected to accelerate the growth of the DNA methylation market” comments a Future Market Insights analyst.
Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15893
Competitive Landscape
Some prominent players in the global DNA methylation market include New England Biolabs, Sysmex Corporation, Abcam plc., F. Hoffmann-La Roche Ltd., Diagenode Diagnostics S.A., Thermo-Fisher Scientific Inc., Agilent Technologies Inc., BioRad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Active Motif, Inc., Illumina Inc.,EpiGentek Group Inc., Pacific Biosciences Inc., New England Biolabs Inc., Merck KGaA, Zymo Research Corporation, PerkinElmer Inc.
- Oxford Nanopore announced the integration of Remora, a technique that provides accurate and real-time epigenetic insights, with nanopore sequencing software in May 2022. This would also make accurate whole-genome methylation detection more accessible.
- Base Genomics announced in June 2020 that it would be advancing and developing its DNA methylation technology. The goal is to sequence a large amount of epigenetic data from a blood test, which could transform the field of preventative medicine.
Key Segments Profiled in the DNA Methylation Industry Survey
Technology:
- Polymerase Chain Reaction (PCR)
- Microarray
- Sequencing
- Others
Product:
- Consumables
- Kits & Reagents
- Enzymes
- Instruments & Software
Application:
- Gene Therapy
- Clinical Research
- Diagnostics
- Others
End-use:
- Hospital & Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Research & Academia
Direct purchase of this report, click here@ https://www.futuremarketinsights.com/checkout/15893
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global DNA methylation market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of technology (Polymerase Chain Reaction (PCR), Microarray, Sequencing, Others), product (Consumables, Kits & Reagents, Enzymes, Instruments & Software), by application (Gene Therapy, Clinical Research, Diagnostics, Others), by end use (Hospital & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Research & Academia) and regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
